Ambrosia Medical (plasma transfusion)

Ambrosia Medical, founded in 2016 at San Francisco by Jesse Karmazin, a Stanford graduate, is a medical start-up company that offers "young blood" (the blood of persons aged 16-25) plasma transfusions, promoting such treatments as having anti-aging and other health benefits. Participants in a preliminary trial of the treatment paid $8000 per 1.5 litres of plasma; the first public prices were set at $8000 per litre, or $12,000 per two litres. The U.S. Food and Drug Administration stated in February 2019 that "there is no proven clinical benefit of infusion of plasma from young donors to cure, mitigate, treat, or prevent these conditions, and there are risks associated with the use of any plasma product;" Ambrosia briefly suspended operations in response, ultimately re-opening its San Francisco clinic in November 2019 and resuming transfusions.

Reading